Pfizer on Wednesday announced that it is reviewing "strategic alternatives" for its drug delivery business unit, Capsugel, which may include divestiture. "The decision to consider strategic alternatives for Capsugel is part of Pfizer's strategy to optimise its business mix," noted Cavan Redmond, head of the company's diversified businesses.
The unit generated $740 million in revenue in 2009, representing about 1.6 percent of Pfizer's total revenues for the year.
An announcement on the results of the review is expected by the end of the first quarter of 2011, Pfizer noted.
To read more Top Story articles, click here.